FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment

FibroBiologics Releases Third cGMP CYWC628 Drug Product Batch For Shipment To Australia, Supporting Ongoing Phase 1/2 Diabetic Foot Ulcer Trial

FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and

FibroBiologics Regains Nasdaq Compliance

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and

8-K filing — FibroBiologics, Inc. (FBLG)

Filed: 2026-08-24 AccNo: 0001193125-26-362027 Size: 202 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

FibroBiologics Says IP Australia Accepted Patent Application No. 2020368344 Covering Cannabidiol Adjuvant Therapy With Fibroblast Cell Therapy For Degenerative Disc Disease